Biogen (BIIB) PT Raised to $275 at Oppenheimer
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $198.04 +0.74%
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 10 | New: 23
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 10 | New: 23
Join SI Premium – FREE
Oppenheimer analyst Jay Olson raised the price target on Biogen (NASDAQ: BIIB) to $275.00 (from $250.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
- International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
- Definium Therapeutics Inc (DFTX) PT Raised to $60 at Oppenheimer
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
